干细胞与再生医学：全球市场

全球干细胞和再生医学市场预计将从 2025 年的 167 亿美元成长到 2030 年的 438 亿美元，2025 年至 2030 年的复合年增长率为 21.3%。

预计北美市场将从 2025 年的 67 亿美元成长到 2030 年的 174 亿美元，2025 年至 2030 年的复合年增长率为 21.2%。

预计亚太市场规模将从 2025 年的 35 亿美元成长到 2030 年的 101 亿美元，2025 年至 2030 年的复合年增长率为 23.2%。

本报告调查了全球干细胞和再生医学市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场概况
• 市场成长要素
• 新兴技术
• 细分市场分析
• 区域分析
• 结论

第二章 市场概览

• 技术背景
• 干细胞
• 胚胎干细胞
• 成体干细胞
• 间质干细胞
• 造血干细胞
• 神经干细胞
• 前驱细胞
• 上皮干细胞
• 超小型胚胎样细胞
• 脐带血干细胞
• 诱导性多功能细胞
• 细胞疗法
• CAR-T细胞疗法简史
• FDA产品核可
• 基因治疗
• 基因治疗的发展
• 宏观经济因素分析
• PESTEL 分析
• 美国关税立法对干细胞和再生医学市场的影响
• 波特五力分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 对再生医学的需求日益增长
• 组织工程产品的研究和监管核准不断增加
• 创业投资资金筹措增加
• 对高效药物发现和开发过程的需求
• 人们越来越关注如何最大限度地减少动物试验
• 市场限制
• 高成本和熟练劳动力短缺
• 复杂的法规结构
• 市场机会
• 技术进步
• iPSC银行的发展

第四章：监理现状

• 概述
• 基因治疗监管
• 细胞治疗法规
• 病毒载体和非病毒载体
• 培养基
• 美国法规结构
• 欧洲法规结构
• 欧洲细胞和基因治疗监管
• 亚太地区法规结构

第五章 新兴科技与新发展

• 概述
• 再程式化技术
• 基因编辑技术
• 3D类器官
• 人工智慧在干细胞研究的应用

第六章 市场区隔分析

• 细分市场分析
• 市场区隔：依产品/服务划分
• 重点总结
• 治疗药物
• 工具和试剂
• 细胞库
• 市场区隔：按应用领域
• 重点总结
• 瘤
• 整形外科
• 糖尿病
• 皮肤科
• 心血管疾病
• 中枢神经系统疾病
• 其他的
• 地理细分
• 市场区隔：依地区划分
• 重点总结
• 北美洲
• 欧洲
• 亚太地区
• 世界其他地区

第七章 竞争讯息

• 重点总结
• 2024年资本利得税市场的主要企业
• 组织工程市场的主要企业
• 战略分析

8. 干细胞与再生医学市场的永续性：ESG视角

• 永续性：干细胞和再生医学市场
• 了解ESG数据
• 主要ESG问题
• 环境绩效
• 社会表现
• 管治绩效
• BCC 的结论

第九章：专利现状

• 重点总结
• 专利审查
• 基因疗法专利（按年份）
• 基因治疗专利（由主要申请人提交）
• 基因治疗专利（依文件类型）
• 细胞疗法专利（按年份）
• 细胞疗法专利（由主要申请人提出）
• 细胞疗法专利（按状态）
• 组织工程专利（按年份）
• 组织工程专利（由主要申请人提出）
• 组织工程专利（按状态）

第十章附录

• 调查方法
• 简称
• 参考
• 公司简介
• ABBVIE INC.
• AMGEN INC.
• BIOGEN
• BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
• BRISTOL-MYERS SQUIBB CO.
• CELLECTIS SA
• CRISPR THERAPEUTICS
• EUREKA THERAPEUTICS INC.
• GILEAD SCIENCES INC.
• MIMEDX GROUP INC.
• NOVARTIS AG
• ORGANOGENESIS INC.
• STRYKER
• TECNOSS
• ZIMMER BIOMET

The global market for stem cell and regenerative therapy is projected to grow from an estimated $16.7 billion in 2025 to $43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.

The North American market for stem cell and regenerative therapy is projected to grow from an estimated $6.7 billion in 2025 to $17.4 billion by 2030, at a CAGR of 21.2% from 2025 to 2030.

The Asia-Pacific market for stem cell and regenerative therapy is projected to grow from an estimated $3.5 billion in 2025 to $10.1 billion by 2030, at a CAGR of 23.2% from 2025 to 2030.

Report Scope

The report provides an overview of the global stem cell and regenerative therapy market and analyzes market trends. The report includes global revenue (in $ millions) for the base year data (2024) and estimated data for the forecast period (2025 through 2030). The market is segmented by product and services, application and region. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with a focus on major countries in each region.

The report focuses on significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies and the patent landscape related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies in the global stem cell and regenerative medicine market, as well as a patent analysis. It also features a section with company profiles that provides overviews, key financials, product portfolios and recent developments of key market companies.

Report Includes

• 50 data tables and 62 additional tables
• Overview and an analysis of the global market for stem cell and regenerative therapy (medicines)
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, along with a corresponding market share analysis based on product and service type, application and region
• Facts and figures pertaining to global market dynamics, advancements in therapy, regulations, prospects and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Patent review, featuring key granted and published patents
• Review of emerging trends and technologies as well as new developments in the stem cell and regenerative therapy market
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives and venture fundings, and an investment outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading companies, including Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb Co., Organogenesis Inc., and MiMedx Group Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Technology Background
• Stem Cell
• Embryonic Stem Cells
• Adult Stem Cells
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Neural Stem Cell
• Endothelial Progenitor Cell
• Epithelial Stem Cell
• Very Small Embryonic-Like Cell
• Cord Blood Stem Cell
• Induced Pluripotent Stem Cells
• Cell Therapy
• A Brief History of CAR-T Cell Therapy
• FDA Product Approvals
• Gene Therapy
• Evolution of Gene Therapy
• Macroeconomic Factors Analysis
• PESTEL Analysis
• Impact of U.S. Tariff Laws on the Stem Cell and Regenerative Therapy Market
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to High)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (High)
• Threat of Substitutes (Low to Moderate)
• Competition in the Industry (High)

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Demand for Regenerative Medicines
• Increasing Research and Regulatory Approval for Tissue Engineering Products
• Rising Venture Capital Funding
• Demand for an Effective Drug Discovery and Development Process
• Rising Focus on Minimizing Animal Testing
• Market Restraints
• High Cost and Lack of Skilled Workforce
• Complex Regulatory Framework
• Market Opportunities
• Technological Advances
• Growth in iPSC Banking

Chapter 4 Regulatory Landscape

• Overview
• Gene Therapy Regulations
• Cell Therapy Regulations
• Viral and Non-Viral Vectors
• Media
• Regulatory Frameworks in the U.S.
• Regulatory Frameworks in Europe
• Cell and Gene Therapy Regulations in Europe
• Regulatory Frameworks in Asia-Pacific

Chapter 5 Emerging Technologies and New Developments

• Overview
• Reprogramming Technologies
• Gene Editing Technologies
• 3D Organoids
• Artificial Intelligence in Stem Cell Research

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Breakdown by Products and Services
• Key Takeaways
• Therapeutics
• Tools and Reagents
• Cell Banking
• Market Breakdown by Application
• Key Takeaways
• Oncology
• Orthopedic
• Diabetes
• Dermatology
• Cardiovascular Disorders
• Central Nervous System Disorders
• Others
• Geographic Breakdown
• Market Breakdown by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Leading Players in the CGT Market, 2024
• Leading Players in the Tissue Engineering Market, 2024
• Strategic Analysis

Chapter 8 Sustainability in the Stem Cell and Regenerative Therapy Market: ESG Perspective

• Sustainability: The Stem Cell and Regenerative Therapy Market
• Understanding the ESG Data
• Key ESG Issues
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 9 Patent Landscape

• Key Takeaways
• Patent Review
• Gene Therapy Patents, by Year
• Gene Therapy Patents, by Leading Applicants
• Gene Therapy Patents, by Document Type
• Cell Therapy Patents, by Year
• Cell Therapy Patents, by Leading Applicants
• Cell Therapy Patents, by Status
• Tissue Engineering Patents, by Year
• Tissue Engineering Patents, by Leading Applicants
• Tissue Engineering Patents, by Status

Chapter 10 Appendix

• Methodology
• Abbreviations
• References
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• BIOGEN
• BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
• BRISTOL-MYERS SQUIBB CO.
• CELLECTIS S.A.
• CRISPR THERAPEUTICS
• EUREKA THERAPEUTICS INC.
• GILEAD SCIENCES INC.
• MIMEDX GROUP INC.
• NOVARTIS AG
• ORGANOGENESIS INC.
• STRYKER
• TECNOSS
• ZIMMER BIOMET

List of Tables

• Summary Table : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
• Table 1 : U.S. FDA-Approved CAR-T Cell Therapies
• Table 2 : Tissue Engineering and Regeneration: Venture Capital Funding, 2024
• Table 3 : Tissue Engineering and Regeneration: Pricing
• Table 4 : Tissue Engineering and Regeneration: Regulatory Overview, 2025
• Table 5 : Brief Information on iPSC Repositories
• Table 6 : Asia-Pacific: Regulatory Landscape, 2024
• Table 7 : Global Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
• Table 8 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
• Table 9 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Region, Through 2030
• Table 10 : Global Market for Stem Cell and Regenerative Therapy for Cell Therapy, by Region, Through 2030
• Table 11 : FDA-Approved Cell-Based Immunotherapy Products
• Table 12 : Approved Human Gene Therapy Products
• Table 13 : Global Market for Stem Cell and Regenerative Therapy for Gene Therapy, by Region, Through 2030
• Table 14 : Global Market for Stem Cell and Regenerative Therapy for Tissue Engineering, by Region, Through 2030
• Table 15 : Recently Launched Stem Cell Reagents, 2024 and 2025
• Table 16 : Global Market for Stem Cell and Regenerative Therapy for Tools and Reagents, by Region, Through 2030
• Table 17 : Global Market for Stem Cell and Regenerative Therapy for Cell Banking, by Region, Through 2030
• Table 18 : Global Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
• Table 19 : Global Market for Stem Cell and Regenerative Therapies for Oncology, by Region, Through 2030
• Table 20 : Orthopedics and Musculoskeletal Disorders: Tissue Engineeringand Regeneration Product
• Table 21 : Global Market for Stem Cell and Regenerative Therapy for Orthopedics, by Region, Through 2030
• Table 22 : Global Market for Stem Cell and Regenerative Therapy for Diabetes, by Region, Through 2030
• Table 23 : Dermatology: Tissue Engineering and Regeneration Products
• Table 24 : Global Market for Stem Cell and Regenerative Therapy for Dermatology, by Region, Through 2030
• Table 25 : Global Market for Stem Cell and Regenerative Therapy for CVDs, by Region, Through 2030
• Table 26 : Global Market for Stem Cell and Regenerative Therapy for Central Nervous System Disorders, by Region, Through 2030
• Table 27 : Global Market for Stem Cell and Regenerative Therapy for Other Applications, by Region, Through 2030
• Table 28 : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
• Table 29 : North American Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
• Table 30 : North American Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
• Table 31 : North American Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
• Table 32 : North American Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
• Table 33 : European Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
• Table 34 : European Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
• Table 35 : European Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
• Table 36 : European Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
• Table 37 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
• Table 38 : Asia-Pacific Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
• Table 39 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
• Table 40 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
• Table 41 : RoW Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
• Table 42 : RoW Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
• Table 43 : RoW Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
• Table 44 : Leading Players, by Ranking, 2024
• Table 45 : Leading Players, by Rank, 2024
• Table 46 : Recent Developments in the Stem Cell and Regenerative Therapy Market, 2023-2025
• Table 47 : ESG Rankings for Major Stem Cell and Regenerative Therapy Companies, 2025*
• Table 48 : ESG: Environmental Overview
• Table 49 : ESG: Social Overview
• Table 50 : ESG: Governance Overview
• Table 51 : Patent Applications Related to Gene Therapy, by Applicant, 2020-2025
• Table 52 : Select Patent Grants for Gene Therapy, 2024 and 2025
• Table 53 : Patent Applications Related to Cell Therapy, by Applicant, 2020-2025
• Table 54 : Select Patents Granted for Cell Therapy, 2024 and 2025
• Table 55 : Patent Applications for Tissue Engineering, by Applicant, 2020-2025
• Table 56 : Select Patents Granted for Tissue Engineering, 2024 and 2025
• Table 57 : Abbreviations Used in the Stem Cell and Regenerative Therapy Market Report
• Table 58 : AbbVie Inc.: Company Snapshot
• Table 59 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 60 : AbbVie Inc.: Product Portfolio
• Table 61 : AbbVie Inc.: News/Key Developments, 2023-2025
• Table 62 : Amgen Inc.: Company Snapshot
• Table 63 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 64 : Amgen Inc.: Product Portfolio
• Table 65 : Amgen Inc.: News/Key Developments, 2024
• Table 66 : Biogen: Company Snapshot
• Table 67 : Biogen: Financial Performance, FY 2023 and 2024
• Table 68 : Biogen: Product Portfolio
• Table 69 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Company Snapshot
• Table 70 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Financial Performance, FY 2023 and 2024
• Table 71 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Product Portfolio
• Table 72 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): News/Key Developments, 2022-2025
• Table 73 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 74 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 75 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 76 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
• Table 77 : Cellectis S.A.: Company Snapshot
• Table 78 : Cellectis S.A.: Financial Performance, FY 2023 and 2024
• Table 79 : Cellectis S.A.: Product Portfolio
• Table 80 : Cellectis S.A.: News/Key Developments, 2023 and 2024
• Table 81 : CRISPR Therapeutics: Company Snapshot
• Table 82 : CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
• Table 83 : CRISPR Therapeutics: Product Portfolio
• Table 84 : CRISPR Therapeutics: News/Key Developments, 2023 and 2024
• Table 85 : Eureka Therapeutics Inc.: Company Snapshot
• Table 86 : Eureka Therapeutics Inc: Product Portfolio
• Table 87 : Eureka Therapeutics Inc.: News/Key Developments, 2023 and 2024
• Table 88 : Gilead Sciences Inc.: Company Snapshot
• Table 89 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 90 : Gilead Sciences Inc.: Product Portfolio
• Table 91 : Gilead Sciences Inc.: News/Key Developments, 2022-2025
• Table 92 : MiMedx Group Inc.: Company Snapshot
• Table 93 : MiMedx Group Inc.: Financial Performance, FY 2023 and 2024
• Table 94 : MiMedx Group Inc.: Product Portfolio
• Table 95 : MiMedx Group Inc.: News/Key Developments, 2022-2024
• Table 96 : Novartis AG: Company Snapshot
• Table 97 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 98 : Novartis AG: Product Portfolio
• Table 99 : Novartis AG: News/Key Developments, 2023 and 2024
• Table 100 : Organogenesis Inc.: Company Snapshot
• Table 101 : Organogenesis Inc.: Financial Performance, FY 2023 and 2024
• Table 102 : Organogenesis Inc.: Product Portfolio
• Table 103 : Stryker: Company Snapshot
• Table 104 : Stryker: Financial Performance, FY 2023 and 2024
• Table 105 : Stryker: Product Portfolio
• Table 106 : Stryker: News/Key Developments, 2025
• Table 107 : Tecnoss: Company Snapshot
• Table 108 : Tecnoss: Product Portfolio
• Table 109 : Zimmer Biomet: Company Snapshot
• Table 110 : Zimmer Biomet: Financial Performance, FY 2023 and 2024
• Table 111 : Zimmer Biomet: Product Portfolio

List of Figures

• Summary Figure : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
• Figure 1 : Historical Development of CAR T-Cell Therapy
• Figure 2 : PESTEL Analysis: Stem Cell and Regenerative Therapy Market
• Figure 3 : Porter's Five Forces Analysis: Stem Cell and Regenerative Therapy Market
• Figure 4 : Market Dynamics of Stem Cell and Regenerative Therapy
• Figure 5 : Number of Scientific Publications on Tissue Engineering, by Year, 2021-2024
• Figure 6 : Phases of the R&D Process
• Figure 7 : Emerging Technologies in the Stem Cell and Regenerative Therapy Market
• Figure 8 : Global Market Shares for Stem Cell and Regenerative Therapy, by Products and Services, 2024
• Figure 9 : Global Market Shares for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, 2024
• Figure 10 : Global Market Shares for Stem Cell and Regenerative Therapy, by Application, 2024
• Figure 11 : T-Cell Therapy Technique
• Figure 12 : Cancer Stem Cell Market, by Type of Cancer
• Figure 13 : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
• Figure 14 : North American Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
• Figure 15 : U.S. Elderly Population (65 and Older), 2010-2050
• Figure 16 : European Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
• Figure 17 : Asia-Pacific Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
• Figure 18 : How a Strong ESG Proposition Benefits Businesses
• Figure 19 : ESG Pillars
• Figure 20 : Patents Granted Related to Gene Therapy, by Year, 2020-2025
• Figure 21 : Patent Shares for Gene Therapy Technology, by Document Type, 2020-2025
• Figure 22 : Patents Granted Related to Cell Therapy, by Year, 2020-2025
• Figure 23 : Patent Shares for Cell Therapy Technology, by Application Status, 2020-2025
• Figure 24 : Patents Granted Related to Tissue Engineering, by Year, 2020-2025
• Figure 25 : Patents Shares for Tissue Engineering, by Application Status, 2020-2025
• Figure 26 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 27 : AbbVie Inc.: Revenue Share, by Region/Country, FY 2024
• Figure 28 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 29 : Amgen Inc.: Revenue Share, by Region/Country, FY 2024
• Figure 30 : Biogen: Revenue Share, by Business Unit, FY 2024
• Figure 31 : Biogen: Revenue Share, by Country/Region, FY 2024
• Figure 32 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
• Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 36 : MiMedx Group Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 37 : Novartis AG: Revenue Share, by Business Unit, FY 2024
• Figure 38 : Novartis AG: Revenue Share, by Country/Region, FY 2024
• Figure 39 : Organogenesis Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 40 : Stryker: Revenue Share, by Business Unit, FY 2024
• Figure 41 : Stryker: Revenue Share, by Country/Region, FY 2024
• Figure 42 : Zimmer Biomet: Revenue Share, by Business Unit, FY 2024
• Figure 43 : Zimmer Biomet: Revenue Share, by Country/Region, FY 2024